Beginning New Clinical Trials, Innovation Recognitions, Expansion in Patent Portfolios, Product Distributions and Offerings - Research Report on Allscripts, Novavax, Amarin, Acura, and Catalyst

Fri Sep 27, 2013 8:00am EDT

* Reuters is not responsible for the content in this press release.

Beginning New Clinical Trials, Innovation Recognitions, Expansion in Patent Portfolios, Product Distributions and Offerings - Research Report on Allscripts, Novavax, Amarin, Acura, and Catalyst

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, September 27, 2013 /PRNewswire/ --

Today, Investors' Reports announced new research reports highlighting Allscripts Healthcare Solutions, Inc. (NASDAQ: MDRX), Novavax, Inc. (NASDAQ: NVAX), Amarin Corporation plc (NASDAQ: AMRN), Acura Pharmaceuticals Inc. (NASDAQ: ACUR), and Catalyst Pharmaceutical Partners Inc. (NASDAQ: CPRX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Allscripts Healthcare Solutions, Inc. Research Report  

On September 6, 2013, Allscripts Healthcare Solutions, Inc. (Allscripts) announced that Baylor Health Care System (Bayer) has been named a winner of the 2013 Tech Titans Technology Adopter Award for its outstanding achievement in the rapid and successful design and implementation of innovations enabled by Allscripts Open solutions platform. The Company stated that Baylor has created various custom components for Allscripts Sunrise Clinical Manager and the enhancements were designed to improve the adoption and use of Computerized Physician Order Entry (CPOE) and the use of electronic physician documentation. According to the Company, the Tech Titans award recognizes companies and individuals who have made outstanding contributions to the technology industry and to the technology industry in North Texas. "We would like to congratulate Baylor for this special recognition," said Paul M. Black, President and CEO of Allscripts. The Full Research Report on Allscripts Healthcare Solutions, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-24/MDRX]

--

Novavax, Inc. Research Report

On September 24, 2013, Novavax, Inc. (Novavax) announced that after a successful completion of process improvement studies, it is now finalizing details on costs and timelines for their next round of clinical studies with the U.S. Department of Health and Human Services, Biomedical Advanced Research and Development Authority (BARDA). The Company informed that it preparing to move forward with these next clinical trials for its quadrivalent seasonal influenza vaccine candidate and its pandemic influenza vaccine candidate, both under U.S. INDs. According to Novavax, it plans to start the Quadrivalent Seasonal Influenza Clinical Trial in Q1 2014 and Pandemic Influenza Clinical Trial in the U.S. in H1 2014. Stanley C. Erck, President and CEO said, "Novavax is committed to moving these two vaccine candidates through to licensure. The clinical trials we have planned for 2014 are important steps in the completion of that goal." The Full Research Report on Novavax, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-24/NVAX]

--

Amarin Corporation plc Research Report

On September 9, 2013, Amarin Corp. plc (Amarin) announced that its flagship product, Vascepa® (icosapent ethyl) capsules now has 30 patents issued or allowed by the United States Patent and Trademark Office (USPTO). Joseph Zakrzewski, Chairman and CEO of Amarin said, "With 30 patents issued and allowed and over 30 additional applications pending in the United States, Amarin now has one of the most extensive, and expanding, patent portfolios covering a product in the industry, The continued issuance of a variety of patents covering Vascepa is emblematic of the success achieved at Amarin toward its goal of protecting the commercial potential of Vascepa to beyond 2030 through patent protection. In addition, Amarin's Vascepa is also protected by trade secrets and existing manufacturing barriers to entry, along with anticipated three- or five-year regulatory exclusivity in the United States." The Full Research Report on Amarin Corporation plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-24/AMRN]

--

Acura Pharmaceuticals Inc. Research Report

On September 18, 2013, Acura Pharmaceuticals Inc. (Acura Pharmaceuticals) announced that its next generation pseudoephedrine hydrochloride tablet, NEXAFED, is now being sold in over 2,600 pharmacies nationwide. The Company informed that the recent increase in stocks of NEXAFED by Pharmacies can be attributed to - Meijer Pharmacies who are stocking NEXAFED in all their pharmacies; the addition of a large regional supermarket chain based in Florida; and further distribution gains at independent pharmacies. Acura Pharmaceuticals stated that NEXAFED is readily available to nearly every pharmacy in the U.S. through national and regional wholesalers. J. Bradley Rivet, Vice President, Marketing with Acura Pharmaceuticals said, "We're seeing a significant increase in repeat orders from pharmacies. We've come to appreciate that once pharmacists begin recommending NEXAFED and are satisfied with its effectiveness, they typically become an advocate." The Full Research Report on Acura Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-24/ACUR]

--

Catalyst Pharmaceutical Partners Inc. Research Report

On September 10, 2013, Catalyst Pharmaceuticals Partners Inc. (Catalyst) reported the closing of its earlier announced offering of $8.8 million shares of its common stock in a registered direct public offering. According to the Company, the offering price was $1.72 per share, with gross proceeds totaling at c.$15.1 million. Patrick J. McEnany, Catalyst's Chairman and CEO, stated, "We are pleased to have completed this financing, which we believe, along with the proceeds from recent warrant exercises, gives us the capital necessary to fund development of Firdapse™ and allows us to begin new clinical studies for CPP-115. We are also excited that several high quality fundamental life science investors, including New Leaf Venture Partners, participated in our offering." The Full Research Report on Catalyst Pharmaceutical Partners Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-24/CPRX]

----

EDITOR NOTES:

  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
  5. For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

InvestorsReports.com

SOURCE Investors' Reports

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.